CompletedPhase 1

Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration

Switzerland, United Kingdom20 participantsStarted 2006-07

Plain-language summary

This study evaluates the tolerability and safety of a single intravenous infusion of ACZ885. It also explores the efficacy of the compound in central macular edema and visual acuity in patients with wet age-related macular edema.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Male or female ≥ 50 years old, with aged related macular degeneration * Patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration Exclusion criteria: * Active intraocular inflammation or ocular infection in the study eye * Eye disease that may result in visual loss during the study * Chronic therapy with topical, local or systemic corticosteroids. * Pregnant or nursing (lactating) women.

What they're measuring

Rates of adverse events and serious adverse events, as well as changes in ophthalmic evaluations, laboratory values, electrocardiograms (ECGs) and vital signs over 6 months, following single intravenous infusion of ACZ885.

Trial details

NCT IDNCT00503022

SponsorNovartis

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Wet Age-Related Macular Degeneration trials